Scalable and commercialisable technology for personalized therapeutic cancer vaccine. No FDA involvement, medical tourism based.
No FDA involvement. R&D and further medical tourism based business development. Current status: 1) provisional patent application is filed, 2) protocols for proof of concept studies are developed, 3) actively looking for partners/investors. Existing technologies are not robust, too complicate, expensive, often lack clinical effectiveness. Anticipated natural immunological mechanisms. Customers: cancer patients. Exit strategy: multiple scenarios.